Advanz Pharma

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair (omalizumab), Accepted by the European Medicines Agency

6 October 2025 -- London, UK and Reykjavik, Iceland -- Advanz Pharma Holdco Limited, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the...
Capital House, 1st Floor, 85 King William Street, London EC4N 7BL

+44 (0) 208 588 9100